Pharming (PHAR) Receivables (2019 - 2026)

Pharming (PHAR) has 8 years of Receivables data on file, last reported at $57.0 million in Q2 2026.

• Quarterly Receivables rose 6.85% year-over-year to $57.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $57.0 million (up 6.85% YoY) and the FY2025 annual result came in at $56.6 million, changed 0.38% from the prior year.
• Receivables eased to $57.0 million in Q2 2026, from $60.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $60.0 million in Q1 2026 to a low of $28828.0 in Q3 2022.
• A 5-year average of $42.3 million and a median of $45.5 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables sank 99.91% — and 2023, when it soared 140461.26%.
• Tracing PHAR's Receivables over 5 years: stood at $28.7 million in 2022, then jumped by 68.09% to $48.3 million in 2023, then gained by 16.8% to $56.4 million in 2024, then rose by 0.38% to $56.6 million in 2025, then advanced by 0.61% to $57.0 million in 2026.
• The last three Receivables figures came in at $57.0 million (Q2 2026), $60.0 million (Q1 2026), and $56.6 million (Q4 2025), per Business Quant data.